Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer

Stock Information for Merus N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Merus N.V.

Merus to Present at the Jefferies Virtual London Healthcare Conference
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
Merus Announces Financial Results for the Third Quarter and Provides Business Update
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
Merus Appoints Andrew Joe, M.D., as Chief Medical Officer
Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates
Merus Announces Pricing of Public Offering of Common Shares
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.